JP2010501567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501567A5 JP2010501567A5 JP2009525617A JP2009525617A JP2010501567A5 JP 2010501567 A5 JP2010501567 A5 JP 2010501567A5 JP 2009525617 A JP2009525617 A JP 2009525617A JP 2009525617 A JP2009525617 A JP 2009525617A JP 2010501567 A5 JP2010501567 A5 JP 2010501567A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- thiazole
- carboxylic acid
- pyrazol
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 125000003118 aryl group Chemical group 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 43
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 27
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 22
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 21
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 108010087894 Fatty acid desaturases Proteins 0.000 claims description 18
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 16
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 16
- -1 trifluoromethoxyl Chemical group 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 125000001475 halogen functional group Chemical group 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 125000004450 alkenylene group Chemical group 0.000 claims description 10
- 125000004419 alkynylene group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000003367 polycyclic group Chemical group 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 claims 3
- 102000055981 human SCD1 Human genes 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- BOSVIHWMSQFDEA-UHFFFAOYSA-N n-benzyl-2-[1-[2-(4-methoxyphenyl)ethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound C1=CC(OC)=CC=C1CCN1N=C(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC=CC=2)C=C1 BOSVIHWMSQFDEA-UHFFFAOYSA-N 0.000 claims 2
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- COFXNWIKPNAICQ-UHFFFAOYSA-N 2-[1-(2-anilinoethyl)pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCNC=3C=CC=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 COFXNWIKPNAICQ-UHFFFAOYSA-N 0.000 claims 1
- DESUOBUOHOUZSF-UHFFFAOYSA-N 2-[1-(2-cyclopropylethyl)pyrazol-3-yl]-n-[(4-fluorophenyl)methyl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC3CC3)C=C2)SC=1C(=O)NCC1=CC=C(F)C=C1 DESUOBUOHOUZSF-UHFFFAOYSA-N 0.000 claims 1
- JROCFBGRHZCVEM-UHFFFAOYSA-N 2-[1-(2-hydroxyethyl)pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCO)C=C2)SC=1C(=O)NCC1=CC=CN=C1 JROCFBGRHZCVEM-UHFFFAOYSA-N 0.000 claims 1
- PASYEHCKCRQQPU-UHFFFAOYSA-N 2-[1-[(3,5-difluorophenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=C(F)C=C(F)C=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 PASYEHCKCRQQPU-UHFFFAOYSA-N 0.000 claims 1
- OGBAAAIKRBXTIV-UHFFFAOYSA-N 2-[1-[(3-chlorophenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=C(Cl)C=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 OGBAAAIKRBXTIV-UHFFFAOYSA-N 0.000 claims 1
- OKMKIHSFKTXQHZ-UHFFFAOYSA-N 2-[1-[(3-cyanophenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=C(C=CC=3)C#N)C=C2)SC=1C(=O)NCC1=CC=CN=C1 OKMKIHSFKTXQHZ-UHFFFAOYSA-N 0.000 claims 1
- FUJCGBTZOLHJSE-UHFFFAOYSA-N 2-[1-[(3-fluorophenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=C(F)C=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 FUJCGBTZOLHJSE-UHFFFAOYSA-N 0.000 claims 1
- WDABMXCIUPNKCF-UHFFFAOYSA-N 2-[1-[(4-chloro-2-fluorophenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C(=CC(Cl)=CC=3)F)C=C2)SC=1C(=O)NCC1=CC=CN=C1 WDABMXCIUPNKCF-UHFFFAOYSA-N 0.000 claims 1
- NVNBSOWRMZEZCP-UHFFFAOYSA-N 2-[1-[(4-chlorophenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=CC(Cl)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 NVNBSOWRMZEZCP-UHFFFAOYSA-N 0.000 claims 1
- AKWDNTBINCFIOL-UHFFFAOYSA-N 2-[1-[(4-cyanophenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=CC(=CC=3)C#N)C=C2)SC=1C(=O)NCC1=CC=CN=C1 AKWDNTBINCFIOL-UHFFFAOYSA-N 0.000 claims 1
- UNFYXLDSTKSWOV-UHFFFAOYSA-N 2-[1-[(4-ethylphenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound C1=CC(CC)=CC=C1CN1N=C(C=2SC(=C(C)N=2)C(=O)NCC=2C=NC=CC=2)C=C1 UNFYXLDSTKSWOV-UHFFFAOYSA-N 0.000 claims 1
- LJCCIMKJGXIMGS-UHFFFAOYSA-N 2-[1-[(4-fluorophenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 LJCCIMKJGXIMGS-UHFFFAOYSA-N 0.000 claims 1
- HUPGKCGSDFOLNY-UHFFFAOYSA-N 2-[1-[(4-tert-butylphenyl)methyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=CC(=CC=3)C(C)(C)C)C=C2)SC=1C(=O)NCC1=CC=CN=C1 HUPGKCGSDFOLNY-UHFFFAOYSA-N 0.000 claims 1
- LYHDTGAYMNXTQQ-UHFFFAOYSA-N 2-[1-[2-(4-fluoroanilino)ethyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCNC=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 LYHDTGAYMNXTQQ-UHFFFAOYSA-N 0.000 claims 1
- ZLTCYIDFMSNXKL-UHFFFAOYSA-N 2-[1-[2-(4-fluorophenoxy)ethyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCOC=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 ZLTCYIDFMSNXKL-UHFFFAOYSA-N 0.000 claims 1
- IBJROADCWLUKIU-UHFFFAOYSA-N 2-[1-[2-(4-fluorophenyl)ethyl]-5-methylpyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC1=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=NC=CC=2)=NN1CCC1=CC=C(F)C=C1 IBJROADCWLUKIU-UHFFFAOYSA-N 0.000 claims 1
- CGTPBDCTPXABEE-UHFFFAOYSA-N 2-[1-[2-(4-fluorophenyl)ethyl]-5-methylpyrazol-3-yl]-n-[(4-fluorophenyl)methyl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC1=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=NN1CCC1=CC=C(F)C=C1 CGTPBDCTPXABEE-UHFFFAOYSA-N 0.000 claims 1
- QLUWINQMTXITCQ-UHFFFAOYSA-N 2-[1-[2-(4-fluorophenyl)ethyl]pyrazol-3-yl]-4-methyl-n-(2-pyridin-3-ylethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCCC1=CC=CN=C1 QLUWINQMTXITCQ-UHFFFAOYSA-N 0.000 claims 1
- LWOSUYHAPVQEBO-UHFFFAOYSA-N 2-[1-[2-(4-fluorophenyl)ethyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 LWOSUYHAPVQEBO-UHFFFAOYSA-N 0.000 claims 1
- XOHQYXIUZYTVJI-UHFFFAOYSA-N 2-[1-[2-(4-fluorophenyl)ethyl]pyrazol-3-yl]-4-methyl-n-pyridin-3-yl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NC1=CC=CN=C1 XOHQYXIUZYTVJI-UHFFFAOYSA-N 0.000 claims 1
- LUBYVOZPGKDWPF-UHFFFAOYSA-N 2-[1-[2-(4-fluorophenyl)ethyl]pyrazol-3-yl]-n-[(4-fluorophenyl)methyl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=C(F)C=C1 LUBYVOZPGKDWPF-UHFFFAOYSA-N 0.000 claims 1
- IMFXAWNWSAISIS-UHFFFAOYSA-N 2-[1-[2-(4-methoxyphenyl)ethyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound C1=CC(OC)=CC=C1CCN1N=C(C=2SC(=C(C)N=2)C(=O)NCC=2C=NC=CC=2)C=C1 IMFXAWNWSAISIS-UHFFFAOYSA-N 0.000 claims 1
- QTKLPOWQQUEGNX-UHFFFAOYSA-N 2-[1-[2-[(4-fluorobenzoyl)amino]ethyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCNC(=O)C=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 QTKLPOWQQUEGNX-UHFFFAOYSA-N 0.000 claims 1
- GSMOTFYLIZJFSZ-UHFFFAOYSA-N 2-[1-[2-[(4-fluorophenyl)sulfonylamino]ethyl]pyrazol-3-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCNS(=O)(=O)C=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 GSMOTFYLIZJFSZ-UHFFFAOYSA-N 0.000 claims 1
- WVYLATFUURTLHK-UHFFFAOYSA-N 2-[3-[4-methyl-5-(pyridin-3-ylmethylcarbamoyl)-1,3-thiazol-2-yl]pyrazol-1-yl]ethyl methanesulfonate Chemical compound CC=1N=C(C2=NN(CCOS(C)(=O)=O)C=C2)SC=1C(=O)NCC1=CC=CN=C1 WVYLATFUURTLHK-UHFFFAOYSA-N 0.000 claims 1
- FBQDWBGOZONRTQ-UHFFFAOYSA-N 2-[6-[(4-fluorophenyl)methyl-methylamino]pyrazin-2-yl]-4-methyl-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=NC=CC=2)=NC=1N(C)CC1=CC=C(F)C=C1 FBQDWBGOZONRTQ-UHFFFAOYSA-N 0.000 claims 1
- IHQVUTRLMXEZMM-UHFFFAOYSA-N 2-[6-[2-(4-fluorophenoxy)ethyl-methylamino]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(O)=O)=NC=1N(C)CCOC1=CC=C(F)C=C1 IHQVUTRLMXEZMM-UHFFFAOYSA-N 0.000 claims 1
- COHIABZYSSAWPB-UHFFFAOYSA-N 2-[6-[2-(4-fluorophenyl)ethyl]pyrazin-2-yl]-n-[(4-fluorophenyl)methyl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(CCC=3C=CC(F)=CC=3)C=NC=2)SC=1C(=O)NCC1=CC=C(F)C=C1 COHIABZYSSAWPB-UHFFFAOYSA-N 0.000 claims 1
- LFQXILYITNIVCS-UHFFFAOYSA-N 2-[6-[[4-(difluoromethoxy)phenyl]methyl-methylamino]pyrazin-2-yl]-n-[(4-fluorophenyl)methyl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=NC=1N(C)CC1=CC=C(OC(F)F)C=C1 LFQXILYITNIVCS-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- NWAKIDXIIAQAQW-UHFFFAOYSA-N 4-methyl-2-[1-(2-phenoxyethyl)pyrazol-3-yl]-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCOC=3C=CC=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 NWAKIDXIIAQAQW-UHFFFAOYSA-N 0.000 claims 1
- XCNRBOGRGUYICM-UHFFFAOYSA-N 4-methyl-2-[1-(2-phenylpropyl)pyrazol-3-yl]-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound C=1C=CC=CC=1C(C)CN(N=1)C=CC=1C(S1)=NC(C)=C1C(=O)NCC1=CC=CN=C1 XCNRBOGRGUYICM-UHFFFAOYSA-N 0.000 claims 1
- XCNRBOGRGUYICM-INIZCTEOSA-N 4-methyl-2-[1-[(2r)-2-phenylpropyl]pyrazol-3-yl]-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound C([C@H](C)C=1C=CC=CC=1)N(N=1)C=CC=1C(S1)=NC(C)=C1C(=O)NCC1=CC=CN=C1 XCNRBOGRGUYICM-INIZCTEOSA-N 0.000 claims 1
- XCNRBOGRGUYICM-MRXNPFEDSA-N 4-methyl-2-[1-[(2s)-2-phenylpropyl]pyrazol-3-yl]-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound C([C@@H](C)C=1C=CC=CC=1)N(N=1)C=CC=1C(S1)=NC(C)=C1C(=O)NCC1=CC=CN=C1 XCNRBOGRGUYICM-MRXNPFEDSA-N 0.000 claims 1
- ANIJWYCYCAMXLW-UHFFFAOYSA-N 4-methyl-2-[1-[(4-methylsulfonylphenyl)methyl]pyrazol-3-yl]-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=CC(=CC=3)S(C)(=O)=O)C=C2)SC=1C(=O)NCC1=CC=CN=C1 ANIJWYCYCAMXLW-UHFFFAOYSA-N 0.000 claims 1
- GRCRTBQDOQHLNV-UHFFFAOYSA-N 4-methyl-2-[1-[(4-pyrazol-1-ylphenyl)methyl]pyrazol-3-yl]-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=CC(=CC=3)N3N=CC=C3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 GRCRTBQDOQHLNV-UHFFFAOYSA-N 0.000 claims 1
- SVALBOALYAAMBS-UHFFFAOYSA-N 4-methyl-2-[1-[2-(n-methylanilino)ethyl]pyrazol-3-yl]-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound C=1C=CC=CC=1N(C)CCN(N=1)C=CC=1C(S1)=NC(C)=C1C(=O)NCC1=CC=CN=C1 SVALBOALYAAMBS-UHFFFAOYSA-N 0.000 claims 1
- BJOYXMHHMOVLRF-UHFFFAOYSA-N 4-methyl-2-[1-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]pyrazol-3-yl]-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)=C(C)N=C1C1=NN(CC=2C=CC(=CC=2)N2N=CN=C2)C=C1 BJOYXMHHMOVLRF-UHFFFAOYSA-N 0.000 claims 1
- PLIMZFASPVYCBJ-UHFFFAOYSA-N 4-methyl-2-[5-methyl-1-[[4-(trifluoromethyl)phenyl]methyl]pyrazol-3-yl]-n-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide Chemical compound CC1=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=NC=CC=2)=NN1CC1=CC=C(C(F)(F)F)C=C1 PLIMZFASPVYCBJ-UHFFFAOYSA-N 0.000 claims 1
- YUWUXPNAEHVSGN-UHFFFAOYSA-N 4-methyl-n-(pyridin-3-ylmethyl)-2-[1-[(4-pyrrol-1-ylphenyl)methyl]pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=CC(=CC=3)N3C=CC=C3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 YUWUXPNAEHVSGN-UHFFFAOYSA-N 0.000 claims 1
- YKLLRTGAZGTGLM-UHFFFAOYSA-N 4-methyl-n-(pyridin-3-ylmethyl)-2-[1-[2-[4-(trifluoromethoxy)phenyl]ethyl]pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC=3C=CC(OC(F)(F)F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 YKLLRTGAZGTGLM-UHFFFAOYSA-N 0.000 claims 1
- JXZFXILVYUEBNU-UHFFFAOYSA-N 4-methyl-n-(pyridin-3-ylmethyl)-2-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=C(C=CC=3)C(F)(F)F)C=C2)SC=1C(=O)NCC1=CC=CN=C1 JXZFXILVYUEBNU-UHFFFAOYSA-N 0.000 claims 1
- XRDMAXCBXHZAJS-UHFFFAOYSA-N 4-methyl-n-(pyridin-3-ylmethyl)-2-[1-[[4-(trifluoromethoxy)phenyl]methyl]pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=CC(OC(F)(F)F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CN=C1 XRDMAXCBXHZAJS-UHFFFAOYSA-N 0.000 claims 1
- XJEWZWJRMRJFBU-UHFFFAOYSA-N 4-methyl-n-(pyridin-3-ylmethyl)-2-[1-[[4-(trifluoromethyl)phenyl]methyl]pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC=3C=CC(=CC=3)C(F)(F)F)C=C2)SC=1C(=O)NCC1=CC=CN=C1 XJEWZWJRMRJFBU-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 229920001268 Cholestyramine Polymers 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- VBEBTNRIGINJJA-UHFFFAOYSA-N N-benzyl-4-methyl-2-[1-(1-phenylethyl)pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound C1=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC=CC=2)=NN1C(C)C1=CC=CC=C1 VBEBTNRIGINJJA-UHFFFAOYSA-N 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102000018692 Sulfonylurea Receptors Human genes 0.000 claims 1
- 108010091821 Sulfonylurea Receptors Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- JLLGRBZBHZHPSL-UHFFFAOYSA-N ethyl 4-[[3-[4-methyl-5-(2-pyridin-3-ylacetyl)-2,5-dihydro-1,3-thiazol-2-yl]pyrazol-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1CN1N=C(C2N=C(C)C(C(=O)CC=3C=NC=CC=3)S2)C=C1 JLLGRBZBHZHPSL-UHFFFAOYSA-N 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 230000002473 insulinotropic effect Effects 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- IKNFPSAIMOUEFA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[6-[(4-fluorophenyl)methyl-methylamino]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC2CC2)=NC=1N(C)CC1=CC=C(F)C=C1 IKNFPSAIMOUEFA-UHFFFAOYSA-N 0.000 claims 1
- KMYXKKYXCVUMSG-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-[1-[2-(1h-indol-3-yl)ethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC=3C4=CC=CC=C4NC=3)C=C2)SC=1C(=O)NCC1=CC=C(F)C=C1 KMYXKKYXCVUMSG-UHFFFAOYSA-N 0.000 claims 1
- VBAAUGQBYHBVNT-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-[1-[2-(4-methoxyphenyl)ethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound C1=CC(OC)=CC=C1CCN1N=C(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)C=C1 VBAAUGQBYHBVNT-UHFFFAOYSA-N 0.000 claims 1
- ZREBOAPYAYXSLR-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-[6-[(3-methoxyphenyl)methyl-methylamino]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound COC1=CC=CC(CN(C)C=2N=C(C=NC=2)C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=C1 ZREBOAPYAYXSLR-UHFFFAOYSA-N 0.000 claims 1
- GYTQYZNZOVHTSR-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-[6-[(4-fluorophenyl)methyl-methylamino]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=NC=1N(C)CC1=CC=C(F)C=C1 GYTQYZNZOVHTSR-UHFFFAOYSA-N 0.000 claims 1
- FWFCXCFSXJCUKS-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-[6-[(4-methoxyphenyl)methyl-methylamino]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound C1=CC(OC)=CC=C1CN(C)C1=CN=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=N1 FWFCXCFSXJCUKS-UHFFFAOYSA-N 0.000 claims 1
- FDZCLWLNBFSEPN-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-[6-[2-(4-methoxyphenoxy)ethyl-methylamino]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound C1=CC(OC)=CC=C1OCCN(C)C1=CN=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=N1 FDZCLWLNBFSEPN-UHFFFAOYSA-N 0.000 claims 1
- NVHZOGAOUCBLSC-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-2-(6-phenylmethoxypyrazin-2-yl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(OCC=3C=CC=CC=3)C=NC=2)SC=1C(=O)NCC1=CC=C(F)C=C1 NVHZOGAOUCBLSC-UHFFFAOYSA-N 0.000 claims 1
- WAFCJISNXFCULQ-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-2-[1-(2-methyl-2-phenylpropyl)pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CC(C)(C)C=3C=CC=CC=3)C=C2)SC=1C(=O)NCC1=CC=C(F)C=C1 WAFCJISNXFCULQ-UHFFFAOYSA-N 0.000 claims 1
- PDHGYOLSCBGQBD-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-2-[1-(2-phenoxyethyl)pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCOC=3C=CC=CC=3)C=C2)SC=1C(=O)NCC1=CC=C(F)C=C1 PDHGYOLSCBGQBD-UHFFFAOYSA-N 0.000 claims 1
- VCZSMYRQDLCBBV-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-2-[6-[3-(2-phenylethyl)pyrrolidin-1-yl]pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(C=NC=2)N2CC(CCC=3C=CC=CC=3)CC2)SC=1C(=O)NCC1=CC=C(F)C=C1 VCZSMYRQDLCBBV-UHFFFAOYSA-N 0.000 claims 1
- KOPOJJSSNIWROC-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-2-[6-[methyl(2-pyridin-2-ylethyl)amino]pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=NC=1N(C)CCC1=CC=CC=N1 KOPOJJSSNIWROC-UHFFFAOYSA-N 0.000 claims 1
- GQJRNMMMKLSKQW-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-2-[6-[methyl(3-phenylpropyl)amino]pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=NC=1N(C)CCCC1=CC=CC=C1 GQJRNMMMKLSKQW-UHFFFAOYSA-N 0.000 claims 1
- XWFGOQZOFHUJKO-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-2-[6-[methyl(pyridin-3-ylmethyl)amino]pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=NC=1N(C)CC1=CC=CN=C1 XWFGOQZOFHUJKO-UHFFFAOYSA-N 0.000 claims 1
- JJAPIHHTKWABOL-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-2-[6-[methyl(pyridin-4-ylmethyl)amino]pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC(F)=CC=2)=NC=1N(C)CC1=CC=NC=C1 JJAPIHHTKWABOL-UHFFFAOYSA-N 0.000 claims 1
- RRLZEMBDKSCPJD-UHFFFAOYSA-N n-benzyl-2-(5-bromopyrazin-2-yl)-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=CC(Br)=NC=2)SC=1C(=O)NCC1=CC=CC=C1 RRLZEMBDKSCPJD-UHFFFAOYSA-N 0.000 claims 1
- SNSYNTMEUZSUJK-UHFFFAOYSA-N n-benzyl-2-(6-benzylpyrazin-2-yl)-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(CC=3C=CC=CC=3)C=NC=2)SC=1C(=O)NCC1=CC=CC=C1 SNSYNTMEUZSUJK-UHFFFAOYSA-N 0.000 claims 1
- OHNWRCKCGSXMOS-UHFFFAOYSA-N n-benzyl-2-(6-chloropyrazin-2-yl)-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(Cl)C=NC=2)SC=1C(=O)NCC1=CC=CC=C1 OHNWRCKCGSXMOS-UHFFFAOYSA-N 0.000 claims 1
- HPFATVYVQHYBJP-UHFFFAOYSA-N n-benzyl-2-[1-(2-cyclohexylethyl)pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC3CCCCC3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 HPFATVYVQHYBJP-UHFFFAOYSA-N 0.000 claims 1
- CQVMYDXXMQCOLT-FQEVSTJZSA-N n-benzyl-2-[1-[(2r)-2-(4-fluorophenyl)-2-hydroxyethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(C[C@H](O)C=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 CQVMYDXXMQCOLT-FQEVSTJZSA-N 0.000 claims 1
- CYNQYUQKILVCSY-FQEVSTJZSA-N n-benzyl-2-[1-[(2r)-2-hydroxy-2-phenylethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(C[C@H](O)C=3C=CC=CC=3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 CYNQYUQKILVCSY-FQEVSTJZSA-N 0.000 claims 1
- CYNQYUQKILVCSY-HXUWFJFHSA-N n-benzyl-2-[1-[(2s)-2-hydroxy-2-phenylethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(C[C@@H](O)C=3C=CC=CC=3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 CYNQYUQKILVCSY-HXUWFJFHSA-N 0.000 claims 1
- VAIMBEBJDMUXRS-UHFFFAOYSA-N n-benzyl-2-[1-[2-(3-fluorophenyl)ethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC=3C=C(F)C=CC=3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 VAIMBEBJDMUXRS-UHFFFAOYSA-N 0.000 claims 1
- AXBXPJURPLQSPM-UHFFFAOYSA-N n-benzyl-2-[1-[2-(4-fluorophenoxy)ethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCOC=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 AXBXPJURPLQSPM-UHFFFAOYSA-N 0.000 claims 1
- HGRDKYCIEAYSPA-UHFFFAOYSA-N n-benzyl-2-[1-[2-(4-fluorophenyl)ethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC=3C=CC(F)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 HGRDKYCIEAYSPA-UHFFFAOYSA-N 0.000 claims 1
- UGCNUNBCUZTXOW-UHFFFAOYSA-N n-benzyl-2-[1-[2-(4-hydroxyphenyl)ethyl]pyrazol-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCC=3C=CC(O)=CC=3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 UGCNUNBCUZTXOW-UHFFFAOYSA-N 0.000 claims 1
- HDSGUOKYJJDUFO-UHFFFAOYSA-N n-benzyl-2-[5-[2-(4-fluorophenyl)ethyl]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=CC(CCC=3C=CC(F)=CC=3)=NC=2)SC=1C(=O)NCC1=CC=CC=C1 HDSGUOKYJJDUFO-UHFFFAOYSA-N 0.000 claims 1
- JYLRTPHRXNYQKP-UHFFFAOYSA-N n-benzyl-2-[6-(dimethylamino)pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CN(C)C1=CN=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC=CC=2)=N1 JYLRTPHRXNYQKP-UHFFFAOYSA-N 0.000 claims 1
- WUJOIVVXTOFJRU-UHFFFAOYSA-N n-benzyl-2-[6-[(4-fluorophenyl)methyl-methylamino]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC=CC=2)=NC=1N(C)CC1=CC=C(F)C=C1 WUJOIVVXTOFJRU-UHFFFAOYSA-N 0.000 claims 1
- DUPJSRQEIOJXIB-FMIVXFBMSA-N n-benzyl-2-[6-[(e)-2-(4-fluorophenyl)ethenyl]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(\C=C\C=3C=CC(F)=CC=3)C=NC=2)SC=1C(=O)NCC1=CC=CC=C1 DUPJSRQEIOJXIB-FMIVXFBMSA-N 0.000 claims 1
- CGLGLWNFCHPFKN-UHFFFAOYSA-N n-benzyl-2-[6-[2-(4-fluorophenoxy)ethyl-methylamino]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound C=1N=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC=CC=2)=NC=1N(C)CCOC1=CC=C(F)C=C1 CGLGLWNFCHPFKN-UHFFFAOYSA-N 0.000 claims 1
- AEVBIYNSSLOWIE-UHFFFAOYSA-N n-benzyl-2-[6-[2-(4-fluorophenyl)ethyl]pyrazin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(CCC=3C=CC(F)=CC=3)C=NC=2)SC=1C(=O)NCC1=CC=CC=C1 AEVBIYNSSLOWIE-UHFFFAOYSA-N 0.000 claims 1
- MBALKBRJRNEXCS-UHFFFAOYSA-N n-benzyl-4-methyl-2-(1h-pyrazol-5-yl)-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2NN=CC=2)SC=1C(=O)NCC1=CC=CC=C1 MBALKBRJRNEXCS-UHFFFAOYSA-N 0.000 claims 1
- KPNNJUWSPXKUQZ-UHFFFAOYSA-N n-benzyl-4-methyl-2-[1-(2-phenoxyethyl)pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCOC=3C=CC=CC=3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 KPNNJUWSPXKUQZ-UHFFFAOYSA-N 0.000 claims 1
- AXGKNLBSHYSJBH-UHFFFAOYSA-N n-benzyl-4-methyl-2-[1-(2-phenylpropyl)pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound C=1C=CC=CC=1C(C)CN(N=1)C=CC=1C(S1)=NC(C)=C1C(=O)NCC1=CC=CC=C1 AXGKNLBSHYSJBH-UHFFFAOYSA-N 0.000 claims 1
- VQJKYGUXJPUYEY-UHFFFAOYSA-N n-benzyl-4-methyl-2-[1-(3-methylbutyl)pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC(C)CCN1C=CC(C=2SC(=C(C)N=2)C(=O)NCC=2C=CC=CC=2)=N1 VQJKYGUXJPUYEY-UHFFFAOYSA-N 0.000 claims 1
- WPQXFAXZKZFIOX-UHFFFAOYSA-N n-benzyl-4-methyl-2-[1-(3-phenylpropyl)pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C2=NN(CCCC=3C=CC=CC=3)C=C2)SC=1C(=O)NCC1=CC=CC=C1 WPQXFAXZKZFIOX-UHFFFAOYSA-N 0.000 claims 1
- AXGKNLBSHYSJBH-KRWDZBQOSA-N n-benzyl-4-methyl-2-[1-[(2r)-2-phenylpropyl]pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound C([C@H](C)C=1C=CC=CC=1)N(N=1)C=CC=1C(S1)=NC(C)=C1C(=O)NCC1=CC=CC=C1 AXGKNLBSHYSJBH-KRWDZBQOSA-N 0.000 claims 1
- AXGKNLBSHYSJBH-QGZVFWFLSA-N n-benzyl-4-methyl-2-[1-[(2s)-2-phenylpropyl]pyrazol-3-yl]-1,3-thiazole-5-carboxamide Chemical compound C([C@@H](C)C=1C=CC=CC=1)N(N=1)C=CC=1C(S1)=NC(C)=C1C(=O)NCC1=CC=CC=C1 AXGKNLBSHYSJBH-QGZVFWFLSA-N 0.000 claims 1
- UHZOCHGUMDRKFR-UHFFFAOYSA-N n-benzyl-4-methyl-2-[5-(3-phenylpropyl)pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=CC(CCCC=3C=CC=CC=3)=NC=2)SC=1C(=O)NCC1=CC=CC=C1 UHZOCHGUMDRKFR-UHFFFAOYSA-N 0.000 claims 1
- GTMQESWOUJKROP-UHFFFAOYSA-N n-benzyl-4-methyl-2-[6-(2-phenylethyl)pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(CCC=3C=CC=CC=3)C=NC=2)SC=1C(=O)NCC1=CC=CC=C1 GTMQESWOUJKROP-UHFFFAOYSA-N 0.000 claims 1
- KQYPATXQBASHAJ-UHFFFAOYSA-N n-benzyl-4-methyl-2-[6-(3-phenylpropyl)pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(CCCC=3C=CC=CC=3)C=NC=2)SC=1C(=O)NCC1=CC=CC=C1 KQYPATXQBASHAJ-UHFFFAOYSA-N 0.000 claims 1
- WCUJIXRJEZFGKN-FMIVXFBMSA-N n-benzyl-4-methyl-2-[6-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(\C=C\C=3C=CC(=CC=3)C(F)(F)F)C=NC=2)SC=1C(=O)NCC1=CC=CC=C1 WCUJIXRJEZFGKN-FMIVXFBMSA-N 0.000 claims 1
- MPLHKNJNLFDAOB-OUKQBFOZSA-N n-benzyl-4-methyl-2-[6-[(e)-2-phenylethenyl]pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(\C=C\C=3C=CC=CC=3)C=NC=2)SC=1C(=O)NCC1=CC=CC=C1 MPLHKNJNLFDAOB-OUKQBFOZSA-N 0.000 claims 1
- OOQMPRBWXAJUFF-UHFFFAOYSA-N n-benzyl-4-methyl-2-[6-[2-[4-(trifluoromethyl)phenyl]ethyl]pyrazin-2-yl]-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2N=C(CCC=3C=CC(=CC=3)C(F)(F)F)C=NC=2)SC=1C(=O)NCC1=CC=CC=C1 OOQMPRBWXAJUFF-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- GWJWYIOSBVKWFI-UHFFFAOYSA-N tert-butyl n-[2-[3-[4-methyl-5-(pyridin-3-ylmethylcarbamoyl)-1,3-thiazol-2-yl]pyrazol-1-yl]ethyl]carbamate Chemical compound CC=1N=C(C2=NN(CCNC(=O)OC(C)(C)C)C=C2)SC=1C(=O)NCC1=CC=CN=C1 GWJWYIOSBVKWFI-UHFFFAOYSA-N 0.000 claims 1
- 201000005665 thrombophilia Diseases 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 3
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82342506P | 2006-08-24 | 2006-08-24 | |
| PCT/US2007/018554 WO2008024390A2 (en) | 2006-08-24 | 2007-08-22 | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010501567A JP2010501567A (ja) | 2010-01-21 |
| JP2010501567A5 true JP2010501567A5 (enExample) | 2010-09-16 |
Family
ID=38951374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525617A Pending JP2010501567A (ja) | 2006-08-24 | 2007-08-22 | 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8314138B2 (enExample) |
| EP (1) | EP2086970B1 (enExample) |
| JP (1) | JP2010501567A (enExample) |
| KR (1) | KR20090040478A (enExample) |
| CN (1) | CN101506203B (enExample) |
| AU (1) | AU2007288245A1 (enExample) |
| BR (1) | BRPI0719122A2 (enExample) |
| CA (1) | CA2661017A1 (enExample) |
| MX (1) | MX2009002019A (enExample) |
| RU (1) | RU2009110254A (enExample) |
| WO (1) | WO2008024390A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110371A1 (es) | 2006-08-15 | 2011-06-24 | Novartis Ag | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA |
| AU2007336238A1 (en) | 2006-12-20 | 2008-06-26 | Novartis Ag | 2-substituted 5-membered heterocycles as SCD inhibitors |
| AU2008241313A1 (en) * | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2707313A1 (en) * | 2007-12-11 | 2009-06-18 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2715947C (en) * | 2008-02-20 | 2016-10-25 | Novartis Ag | Heterocyclic inhibitors of stearoyl-coa desaturase |
| GB0810913D0 (en) * | 2008-06-13 | 2008-07-23 | Smithkline Beecham Corp | Comppounds |
| US20110184027A1 (en) * | 2008-09-25 | 2011-07-28 | Glenmark Pharmaceuticals S.A. | Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification |
| DE102008057344A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102008057343A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102008057364A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102009041242A1 (de) | 2009-09-11 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102009041241A1 (de) | 2009-09-11 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Substituierte Aryl-Verbindungen und ihre Verwendung |
| FR2938538B1 (fr) * | 2008-11-17 | 2011-08-05 | Univ Nice Sophia Antipolis | Procede de preparation d'acides et d'esters boroniques en presence de magnesium metallique |
| WO2010094120A1 (en) | 2009-02-17 | 2010-08-26 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US8383643B2 (en) | 2009-07-28 | 2013-02-26 | Merck Canada Inc. | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| AU2010302577A1 (en) * | 2009-10-01 | 2012-03-15 | Novartis Ag | Pyrazole derivatives which modulate stearoyl-CoA desaturase |
| TWI532737B (zh) | 2010-06-30 | 2016-05-11 | 艾諾屋製藥公司 | 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物 |
| JP5878546B2 (ja) | 2010-11-09 | 2016-03-08 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激剤 |
| US9358250B2 (en) | 2011-10-15 | 2016-06-07 | Genentech, Inc. | Methods of using SCD1 antagonists |
| CA2861804C (en) | 2011-12-27 | 2021-10-26 | Ironwood Pharmaceuticals, Inc. | 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators |
| WO2013134546A1 (en) | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| MX2014014174A (es) | 2012-05-22 | 2015-07-06 | Hoffmann La Roche | Inhibidores selectivos de celulas no diferenciadas. |
| CN103694195B (zh) * | 2013-09-18 | 2016-04-06 | 华东师范大学 | 芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途 |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| WO2016101118A1 (en) * | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Amidoethyl azole orexin receptor antagonists |
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| CN118286225A (zh) * | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659726A (en) | 1984-04-19 | 1987-04-21 | Kanebo, Ltd. | Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same |
| IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| EP0471201A1 (de) | 1990-07-21 | 1992-02-19 | Hoechst Aktiengesellschaft | Neue Oxazolidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen |
| JPH04247076A (ja) | 1991-02-01 | 1992-09-03 | Canon Inc | 液晶性化合物、これを含む液晶組成物、およびその使用方法、それを使用した液晶素子、表示装置 |
| EP0520292A1 (de) | 1991-06-19 | 1992-12-30 | Hoechst Aktiengesellschaft | Chirale Azetidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen |
| IT1254199B (it) | 1992-02-06 | 1995-09-14 | Ministero Dell Uni E Della | Tiazolilpirroli ad attivita' fungicida |
| US5254576A (en) | 1992-04-03 | 1993-10-19 | Bristol-Myers Squibb Company | Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors |
| DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| JP3377826B2 (ja) | 1993-05-06 | 2003-02-17 | ヘキスト・アクチェンゲゼルシャフト | 液晶組成物に使用するための新規化合物 |
| FR2707295A1 (fr) * | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
| US6359134B1 (en) | 1997-05-30 | 2002-03-19 | Takeda Chemical Industries, Ltd. | Sulfonamide derivatives, their production and use |
| AU751139B2 (en) * | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
| ATE229945T1 (de) | 1998-03-19 | 2003-01-15 | Upjohn Co | Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole |
| US6399656B1 (en) | 1998-07-28 | 2002-06-04 | Smithkline Beecham Corporation | Compounds and methods |
| EP1126833A4 (en) | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES |
| AU2164300A (en) | 1998-12-04 | 2000-06-26 | N.V. Organon | Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin |
| DK1161438T3 (da) * | 1999-03-15 | 2004-08-30 | Abbott Lab | 6-O-substituerede makrolider, som har antibakteriel aktivitet |
| US6054435A (en) * | 1999-03-19 | 2000-04-25 | Abbott Laboratories | 6-O-substituted macrolides having antibacterial activity |
| AU2001238424A1 (en) | 2000-02-18 | 2001-08-27 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU2001243158A1 (en) | 2000-02-18 | 2001-08-27 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| EP1315831B8 (en) | 2000-02-24 | 2010-09-01 | Xenon Pharmaceuticals Inc. | Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| EP1184442A1 (en) | 2000-08-30 | 2002-03-06 | Clariant International Ltd. | Liquid crystal mixture |
| EP1322767B1 (en) | 2000-09-26 | 2008-07-23 | Xenon Pharmaceuticals Inc. | Methods and compositions employing a stearoyl-coa desaturase-hscd5 |
| AR035205A1 (es) | 2000-09-29 | 2004-05-05 | Glaxo Group Ltd | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas |
| JP2002114784A (ja) | 2000-10-06 | 2002-04-16 | Nissan Chem Ind Ltd | イソキサゾール誘導体および有害生物防除剤 |
| JP2004531471A (ja) * | 2000-12-21 | 2004-10-14 | グラクソ グループ リミテッド | マクロライド抗生物質 |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| DE60234264D1 (de) | 2001-10-01 | 2009-12-17 | Bristol Myers Squibb Co | Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen |
| US6824707B2 (en) | 2001-10-23 | 2004-11-30 | Clariant International Ltd. | Active matrix liquid crystal device and smectic liquid crystal mixture |
| GB0208579D0 (en) | 2002-04-13 | 2002-05-22 | British Biotech Pharm | Antibacterial agents |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| EP1583531B1 (en) * | 2003-01-16 | 2007-04-18 | SB Pharmco Puerto Rico Inc | Heteroaryl-substituted pyrrolo[2, 3- b]pyridine derivatives as crf receptor antagonists |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP1601657A1 (en) | 2003-03-12 | 2005-12-07 | Vertex Pharmaceuticals Incorporated | Pyrazole modulators of atp-binding cassette transporters |
| EP1615931A1 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazines and methods of making and using the same |
| WO2004089415A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| DE602004027171D1 (de) | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| CA2523336A1 (en) | 2003-04-30 | 2004-11-11 | Merck Frosst Canada Ltd. | 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors |
| GB0320244D0 (en) | 2003-05-06 | 2003-10-01 | Aventis Pharma Inc | Pyrazoles as inhibitors of tumour necrosis factor |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2005011654A2 (en) | 2003-07-29 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
| US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| KR20060037410A (ko) | 2003-07-30 | 2006-05-03 | 제논 파마슈티칼스 인크. | 피리다진 유도체 및 그의 치료제로서의 용도 |
| EP2316827B1 (en) | 2003-07-30 | 2016-01-27 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| KR20060037409A (ko) | 2003-07-30 | 2006-05-03 | 제논 파마슈티칼스 인크. | 피페라진 유도체 및 그의 치료제로서의 용도 |
| ES2397389T3 (es) | 2003-07-30 | 2013-03-06 | Xenon Pharmaceuticals Inc. | Derivados de piridilo y su uso como agentes terapéuticos |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| CN1618796A (zh) | 2003-11-21 | 2005-05-25 | 吉林省药物研究所 | 4，5－二取代－2－（1－取代－1h－吡咯－2－基）－噻唑衍生物 |
| CA2551178C (en) | 2003-12-24 | 2012-11-06 | Biota Scientific Management Pty Ltd | Polycyclic agents for the treatment of respiratory syncytial virus infections |
| GB0402496D0 (en) | 2004-02-04 | 2004-03-10 | Argenta Discovery Ltd | Novel compounds |
| NZ549003A (en) | 2004-03-05 | 2009-07-31 | Taisho Pharmaceutical Co Ltd | Thiazole derivative as an ALK5 inhibitor |
| GB0406280D0 (en) | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Chemical compounds |
| GB0406279D0 (en) | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| US20070293482A1 (en) | 2004-03-19 | 2007-12-20 | Novartis Pharmaceuticals Corporation | Process for Preparing Benzodiazepines |
| TW200538127A (en) | 2004-04-07 | 2005-12-01 | Millennium Pharm Inc | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| EP1753734A1 (en) | 2004-05-05 | 2007-02-21 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
| US8134010B2 (en) | 2004-05-05 | 2012-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof |
| JP2008503446A (ja) | 2004-05-06 | 2008-02-07 | プレキシコン，インコーポレーテッド | Ｐｄｅ４ｂ阻害剤及びその使用 |
| US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| KR100926203B1 (ko) | 2004-07-02 | 2009-11-09 | 제넨테크, 인크. | Ｉａｐ의 억제제 |
| BRPI0418939A (pt) | 2004-07-06 | 2008-04-08 | Xenon Pharmaceuticals Inc | derivados de nicotinamida e sua utilização como agentes terapêuticos |
| BRPI0515012A (pt) | 2004-08-13 | 2008-07-01 | Genentech Inc | substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1804799B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| JP4958787B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体 |
| US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| EP1799667B1 (en) | 2004-09-20 | 2013-03-20 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| CN101083986A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途 |
| CA2580856A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| EP1820504A1 (en) | 2004-11-15 | 2007-08-22 | Taisho Pharmaceutical Co., Ltd | Imine compound |
| CN1834095B (zh) | 2005-03-18 | 2011-04-20 | 中国科学院上海药物研究所 | 一类非核苷类抗病毒抑制剂及其制备方法和用途 |
| AU2006244203B2 (en) | 2005-05-09 | 2012-05-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| WO2007046867A2 (en) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| WO2006125181A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their use as stearoyl-coa desaturase modulators |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| WO2006125180A1 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2006125178A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic pyridazine compounds and their uses as therapeutic agents |
| WO2006125179A1 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| WO2006125194A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2007046868A2 (en) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Thiazolidine derivatives and their uses as therapeutic agents |
| EP1902051A1 (en) | 2005-06-09 | 2008-03-26 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP1894930A4 (en) | 2005-06-23 | 2010-06-23 | Kyowa Hakko Kirin Co Ltd | THIAZOLE DERIVATIVE |
| WO2007009236A1 (en) | 2005-07-20 | 2007-01-25 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| DK1921077T3 (en) | 2005-08-02 | 2017-10-23 | Kyowa Hakko Kirin Co Ltd | Means for treating and / or preventing sleep disorders |
| JP2007126454A (ja) | 2005-10-06 | 2007-05-24 | Taisho Pharmaceut Co Ltd | アニリド誘導体 |
| AU2006315025A1 (en) | 2005-11-15 | 2007-05-24 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AU2006327317B2 (en) * | 2005-12-23 | 2010-11-25 | Astrazeneca Ab | GABA-B receptor modulators |
| CA2639913A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceutical Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| WO2008019357A2 (en) * | 2006-08-07 | 2008-02-14 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
-
2007
- 2007-08-22 BR BRPI0719122-7A patent/BRPI0719122A2/pt not_active Application Discontinuation
- 2007-08-22 RU RU2009110254/04A patent/RU2009110254A/ru not_active Application Discontinuation
- 2007-08-22 US US12/438,654 patent/US8314138B2/en not_active Expired - Fee Related
- 2007-08-22 CA CA002661017A patent/CA2661017A1/en not_active Abandoned
- 2007-08-22 JP JP2009525617A patent/JP2010501567A/ja active Pending
- 2007-08-22 KR KR1020097005864A patent/KR20090040478A/ko not_active Withdrawn
- 2007-08-22 EP EP07811474.1A patent/EP2086970B1/en not_active Not-in-force
- 2007-08-22 WO PCT/US2007/018554 patent/WO2008024390A2/en not_active Ceased
- 2007-08-22 MX MX2009002019A patent/MX2009002019A/es not_active Application Discontinuation
- 2007-08-22 AU AU2007288245A patent/AU2007288245A1/en not_active Abandoned
- 2007-08-22 CN CN200780031571XA patent/CN101506203B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200038342A1 (en) | Fatty acid cysteamine conjugates and their use as activators of autophagy | |
| US10968172B2 (en) | USP30 inhibitors | |
| CN101622231B (zh) | 作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用 | |
| JP7418227B2 (ja) | 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法 | |
| AU2016204410B2 (en) | Methods for treating vascular leak syndrome | |
| DE60027420T2 (de) | Tri-aryl-säurederivate als ppar rezeptor liganden | |
| US20130172391A1 (en) | Pharmaceutical compositions | |
| JP2008513499A5 (enExample) | ||
| RU2009110254A (ru) | Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений | |
| US20090270394A1 (en) | Cyclylamine derivatives as calcium channel blockers | |
| JP2011521907A5 (enExample) | ||
| KR20170123658A (ko) | 장 수용체를 활성화시키는 파네소이드 x 수용체 작용제를 사용한 성인 잠복성 자가면역 당뇨병의 치료 | |
| US20100305139A1 (en) | Method of treating abnormal lipid metabolism | |
| US20090012010A1 (en) | Amino acid derivatives as calcium channel blockers | |
| WO2011136307A1 (ja) | 夜間頻尿の予防又は治療剤 | |
| JP7549344B2 (ja) | 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 | |
| WO2011136308A1 (ja) | 泌尿器疼痛を伴う疾患の予防又は治療剤 | |
| US9096554B2 (en) | Drugs for inhibiting p38 and uses thereof | |
| Sharma et al. | Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia-a review | |
| US9050347B2 (en) | 1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor | |
| WO2011002011A1 (ja) | Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬 | |
| JP6850730B2 (ja) | 緑内障予防治療剤 | |
| US20230100367A1 (en) | Methods of treating cdgsh iron sulfur domain 2 insufficiency-associated disorders | |
| CN1938020A (zh) | 离子通道调节剂 | |
| AU2008201550B2 (en) | Method of inhibiting remnant lipoprotein production |